Trial Profile
Phase II Study of Bi-Weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 28 Mar 2017 Status changed from active, no longer recruiting to completed.
- 01 Apr 2014 Planned end date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 01 Apr 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.